Friday, January 4, 2013

Heroin Use in Florida Grows as Opioids Become More Difficult to Abuse


As opioids become more difficult and expensive to abuse, heroin use is on the rise in Florida, according to law enforcement officials. A similar trend has been reported around the country.
The Miami Herald reports an analysis of drug-related deaths in 2011 shows heroin is one of the state’s most harmful drugs. Heroin-related deaths increased by 18.8 percent, to 62 deaths, compared with the previous year. The number of deaths from heroin use is down from a high of 270 in 2001, the newspaper notes.
The recent increase is worrying to local drug rehabilitation experts. They report seeing more patients who have switched from oxycodone or other prescription drugs to heroin in the last year.
“When I ask my patients, they say, ‘Yeah, I couldn’t get oxycodone, and now I’m using heroin, four or five bags,’” Dr. Patricia Junquera of Jackson Memorial Hospital’s detox unit told the newspaper. “I think more people are switching to heroin.’’
A study published in July 2012 found OxyContin abuse has decreased now that the painkiller has been reformulated to make it more difficult to misuse. Many people who abused the drug have switched to heroin, the researchers reported in the New England Journal of Medicine. In 2010, the company that makes OxyContin introduced a new version of the drug that is more difficult to inhale or inject.
Florida has taken a number of measures in the past several years designed to reduce prescription drug abuse. In June 2011, Florida Governor Rick Scott signed into law a bill designed to cut down on prescription drug abuse by controlling “pill mills” in the state. The law authorized the creation of a prescription-drug monitoring database to reduce doctor-shopping by people looking to collect multiple painkiller prescriptions. The legislation also imposed new penalties for physicians who overprescribe medication and imposes stricter rules for operating pharmacies.

CADCA National Leadership Forum to be Held February 4-7



Registration is open for Community Anti-Drug Coalitions of America (CADCA)’s 23rd annual National Leadership Forum, to be held February 4-7 in National Harbor, Maryland. The CADCA Forum is the nation’s largest training conference for community prevention and treatment professionals and researchers.
The meeting’s theme is “Science, Strategies & Solutions.” More than 2,700 participants are expected to attend, including leaders of community anti-drug coalitions, government leaders, youth, addiction treatment professionals, researchers, law enforcement professionals, educators and faith-based leaders.
Workshops will help participants develop comprehensive evidence-based strategies to create community-level change. Presenters will include Gil Kerlikowske, Director of the Office of National Drug Control Policy; Pamela Hyde, Substance Abuse and Mental Health Services Administration Administrator; Michele Leonhart, Drug Enforcement Administration Administrator; and California Congresswoman Mary Bono Mack. For more information, visit CADCA’s Forum website.

Navy Unveils Video Demonstrating Worrisome Effects of Bath Salts


The U.S. Navy has released a video that demonstrates the disturbing effects of bath salts, ABC News reports. The video is the latest weapon in the Navy’s effort to combat synthetic drug use.
The video shows a sailor who snorts bath salts. Shortly afterwards he vomits, then starts having hallucinations. His girlfriend appears demonic to him, and he assaults her. He collapses and wakes up in restraints as he is brought to the hospital, clearly in distress.
“When people are using bath salts, they’re not their normal selves,” Lt. George Loeffler, a Psychiatry Resident at the Naval Medical Center in San Diego, tells viewers. “They’re angrier. They’re erratic. They’re violent and they’re unpredictable…People will start seeing things that aren’t there, believing things that aren’t true.”
Loeffler adds the effects of paranoia brought on by bath salts can last days or weeks after the drugs have left the body.
Synthetic drugs such as bath salts and synthetic marijuana fall under the Navy’s Zero Tolerance policy. Sailors found to be using, possessing, distributing or who observe an abuse and do not report the incident can be charged with violating the Navy’s policies.

http://myemail.constantcontact.com/RIR--Hurricane-Relief-Benefit-Concert--Final-Lineup-and-Update.html?soid=1102906894456&aid=Y5UATecfSQo

http://myemail.constantcontact.com/RIR--Hurricane-Relief-Benefit-Concert--Final-Lineup-and-Update.html?soid=1102906894456&aid=Y5UATecfSQo

Thursday, January 3, 2013

Ethics CEs through NAADAC

Over 19 CEs of Ethics Education
Ethics and equity and the principles of justice do not change with the calendar.  - D. H. Lawrence
 
Brush up on your Ethics with continuing education through NAADAC.  Gain CE credit from your home, prepare for an upcoming certification/licensure exam and maintain your current state and national credentials.

Browse all CEs in Ethics

Become a member of NAADAC to earn free CE credit for all NAADAC webinars & online courses (over 85 CEs): www.naadac.org/join
Free On Demand Ethics Webinars
Watch at your convenience 24/7
CE credit available by passing online CE quiz: Free for NAADAC members; $15-25 for non-members
Ethics and Professional Issues in Addiction Counseling Independent Study Course
 
Course includes a spiral-bound study manual and 30 written examination questions.  Earn 12 CEs!

Click here for a sneak peak inside!

Can be used as a stand-alone resource for those seeking additional guidance in ethics or to help prepare for a state or national examination.
 
NAADAC Master Calendar

Find NAADAC sponsored conferences, public policy events, regional meetings, and ethics workshops in your area with the NAADAC Master Calendar.

Pledge the NAADAC Code of Ethics

Read the NAADAC Code of Ethics

Download the new NAADAC Code of Ethics in English or Spanish

25% Off Bookstore 

NAADAC has many books, training manuals and independent study courses from which to choose, all 25% off!
 
Click here to browse store
Like on Facebook
Like on Facebook
Follow on Twitter
Follow on Twitter
Join LinkedIn Group
Join LinkedIn Group
NAADAC Website
NAADAC Website

NAADAC, The Association for Addiction Professionals
1001 North Fairfax Street, Suite 201
Alexandria, VA 22314
703.741.7686
www.naadac.org

 

Questions? Email Misti Storie

Update Your Profile

Forward to a Friend

Subscribe to this Email List

Unsubscribe? unsubscribe from this list 
(Immediate removal - Please do NOT report as "spam" or "junk")

Drug Companies Want Ban on Generic Painkillers, Arguing Safety is at Stake


Drug companies that manufacture the painkillers OxyContin and Opana are trying to block generic drug makers’ efforts to produce cheaper versions of the drugs. They argue these newer drugs will not have the tamper-resistant designs used in making the brand-name pills, according to The New York Times.
Generic versions of the two painkillers are expected to be significantly less expensive than the brand-name drugs.
Purdue Pharma, which makes OxyContin, and Endo Pharmaceuticals, which manufactures Opana, produce versions of the drugs that are more resistant to melting or crushing, which makes them more difficult to abuse. The companies say generic versions of the drugs without these safety features will increase demand for the drugs and lead to a rise in painkiller abuse.
Both companies support state and federal legislation that would require many opioids to be tamper-resistant, the article notes. The manufacturers are also asking the Food and Drug Administration (FDA) to differentiate between drugs with tamper-resistant features and those without such qualities.
A bill introduced in the U.S. House this summer would require most painkillers to have safeguards to prevent abuse. Under the provisions of the bill, most prescription painkillers would have some form of abuse deterrence, such as being more difficult to crush or inject. If pain medications did not adopt the safety features outlined in the bill, they would be removed from the FDA’s approved list of generic drugs.
In December, a federal judge threw out a lawsuit by Endo that aimed to block the FDA from allowing generic versions of Opana. The newspaper quotes court papers filed in response to Endo’s lawsuit, in which the FDA called the company’s action a “thinly veiled attempt to maintain its market share and block generic competition.”